23 May 2013
Keywords: b-ms, backs, off, higher, offer, imclone, following
Article | 13 October 2008
Following Eli Lilly's $70-a-share counter bid for US biotechnology firm ImClone, Bristol-Myers Squibb, which had been trying to gain control ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
13 October 2008
© 2013 thepharmaletter.com